ARTICLE | Clinical News
Xalkori crizotinib: Phase III data
November 23, 2015 8:00 AM UTC
Top-line data from the open-label, Asian Phase III PROFILE 1029 trial in about 200 previously untreated ALK-positive advanced non-squamous NSCLC patients showed that twice-daily 250 mg oral Xalkori me...